Rx Medicare

NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), announced that the Company’s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (http://www.terrapinn.com/usaflu). The discussion will center on the “Evolving Role of Anti-Virals” in influenza treatment. Dr.

Read More…

Related Posts

• NanoViricides Presents FluCide™ Animal Study Data At Influenza Congress – Now Improved Substantially And Vastly Superior To Current Treatment
• Diagnostic Hybrids Receives FDA Emergency Use Authorization For D3 Ultra 2009 H1N1 Influenza A Virus ID Kit
• Toward A Less Expensive Version Of The Anti-flu Drug Tamiflu
• Swine Influenza Daily Update: 24 December 2009, Wales
• Swine Influenza Daily Update: 29 December 2009, Wales
• Swine Influenza Daily Update: 16 December 2009, Wales
• Swine Influenza Daily Update: 01 December 2009, Wales
• Swine Influenza Daily Update: 06 December 2009, Wales
• Swine Influenza Daily Update: 24 November 2009, Wales
• Groups At High Risk Of H1N1 Influenza A Should Avoid Travelling To 2009 HAJJ
• FDA Approves Additional Vaccine For 2009 H1N1 Influenza Virus
• CSL Biotherapies Obtains FDA Licensure For Use Of Its Thimerosal-Free Pandemic Influenza A (H1N1) 2009 Monovalent Vaccine In Children
• Swine Influenza Daily Update: 09 November 2009, Wales
• USDA Conducting Confirmatory Testing On Possible Detection Of 2009 Pandemic H1N1 Influenza In U.S. Swine
• Cherokee County Death Linked To 2009 H1N1 Influenza

Tags: 2009, anti, candidate, congress, drug, efficacy, flucide%e2%84%a2, influenza, nanoviricides, present, studies

This entry was posted on Wednesday, November 11th, 2009 at 12:11 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.